KLUS Pharma Inc

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
Founded in 2014 as a wholly owned subsidiary of Kelun Group and affiliated company of Kelun-Biotech, KLUS Pharma is committed to the discovery and development of advanced therapeutic biotechnologies. We put patient needs at a paramount priority and are devoted to treatment of advanced cancers, cardiovascular diseases, autoimmune diseases, and other severe disorders. Relying on our innovative platforms of monoclonal antibodies, bi-specific antibodies, and Antibody-Drug Conjugates (ADCs), several biological drugs with novel mechanisms and superior efficacy have advanced into clinical phases.

KLUS Pharma developed and integrated antibody discovery and engineering capabilities, which enable seamless transition from target discovery to technology development. LUS Pharma have identified/assessed dozens of therapeutic targets and is conducting preclinical and clinical studies for over 10 antibody-based therapeutics.
Company Type:
Company Website:
Company HQ State:
New Jersey
Company HQ Country:
United States
Year Founded:
2014
Main Therapeutic Focus:
Lead Product in Development:
A264, A166, antibody-drug conjugates
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
4
Speaker
photo
Associate Director, Business Development
KLUS Pharma Inc.